SCHEMBL249720

SCHEMBL249720

Nc1ccc(C(=O)O)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 11/20 0.59
P4HA1 P13674 1/20 0.59
MIF P14174 1/20 0.59
KDM4E B2RXH2 5/20 0.57
ALDH1A1 P00352 2/20 0.57
L3MBTL1 Q9Y468 4/20 0.50
KMT2A Q03164 2/20 0.50
HIF1A Q16665 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
GLA P06280 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPK1 P28482 1/20 0.48
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31359466 1.00 P4HTM (0.59) P4HTMP4HA1MIFKDM4EALDH1A1
Hydrochloric Acid SCHEMBL21485420 0.98 P4HTM (0.57) P4HTMP4HA1MIFKDM4EALDH1A1
Methylamine SCHEMBL3235636 0.96 P4HTM (0.55) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL7946346 0.87 MAP4K4 (0.48) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL10487101 0.86 P4HTM (0.50) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL30859509 0.84 P4HTM (0.44) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL254682 0.84 MAP4K4 (0.55) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL1831265 0.82 KMT2A (0.55) P4HTMP4HA1MIFKDM4EALDH1A1
Hydrazine SCHEMBL10487110 0.82 P4HTM (0.47) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL22239228 0.80 SIRT6 (0.41) P4HTMP4HA1MIFKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122060177-A Preparation method of alkaline functionalized I-type porous liquid and application of alkaline functionalized I-type porous liquid in CO2Separation and transformation 南京大学 2026-05-19 CN claimed
US-20250066570-A1 LAMINATE DEVICE WITH METALLIC AND POLYMER LAYERS QUANTUM MICROMATERIALS INC (US) 2025-02-27 US claimed
CN-118755400-B Low VOCSAdhesive tape and preparation method thereof 江阴邦特新材料科技股份有限公司 2025-01-28 CN claimed
CN-119300599-A Perovskite crystal silicon laminated solar cell structure, preparation method and cell 江苏先导微电子科技有限公司 2025-01-10 CN claimed
CN-118755400-A Low VOCSAdhesive tape and preparation method thereof 江阴邦特新材料科技股份有限公司 2024-10-11 CN claimed
US-20230357578-A1 AIRTIGHT FILM WITH CERAMIC SEALING LAYER AND POLYMER SEALING LAYER Quantum MicroMaterials, Inc. 2023-11-09 US claimed
CN-115403517-B Organic-inorganic hybrid heteropolyacid solid tackifier, preparation method and dealcoholized silicone adhesive 万华化学集团股份有限公司 2023-08-11 CN claimed
CN-115403517-A Organic-inorganic hybrid heteropoly acid solid tackifier, preparation method and dealcoholized silicone adhesive 万华化学集团股份有限公司 2022-11-29 CN claimed
CN-114456756-A Epoxy resin underfill 惠州市飞世尔实业有限公司 2022-05-10 CN claimed
CN-112438253-A Saliva preserving fluid and preparation method thereof 武汉吉诺百客医学科技有限公司 2021-03-05 CN claimed
US-20070111075-A1 Branched multiblock polybenzimidazole-benzamide copolymer and method for preparing the same, electrolyte membrane and paste/gel prepared therefrom LG CHEM, LTD. (KR) 2007-05-17 US claimed
US-20040101523-A1 Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension G.D. SEARLE & CO. 2004-05-27 US claimed
US-20030220521-A1 Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension G.D. SEARLE & CO. 2003-11-27 US claimed
EP-0573581-A4 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1 INC (US) 1994-06-29 EP claimed
EP-0484437-A4 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION SEARLE & CO (US) 1994-06-01 EP claimed
EP-0573581-A1 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1, Inc. (US) 1993-12-15 EP claimed
WO-1992014453-A1 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1, INC. (US) 1992-09-03 WO claimed
EP-0484437-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. Searle & Co. (US) 1992-05-13 EP claimed
WO-1992001667-A1 RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1992-02-06 WO claimed
WO-1991001724-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1991-02-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220521-A1 Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension GLS, APEH, GGH P4HTM 257/4885P4HA1 167/4885MIF 4264/4885
US-20040101523-A1 Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension GLS, DBH, APEH P4HTM 296/4885P4HA1 258/4885MIF 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.